Interestingly, also, Bryostatin-1, a PKC activator failed in clinical trial in cervical cancer patients, however, this is likely to due to the effects this compound has on down-regulating PKCs [49–51]. This evidence concerns the gene PRRT2 and cervical carcinoma.